JP2019501142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501142A5 JP2019501142A5 JP2018527919A JP2018527919A JP2019501142A5 JP 2019501142 A5 JP2019501142 A5 JP 2019501142A5 JP 2018527919 A JP2018527919 A JP 2018527919A JP 2018527919 A JP2018527919 A JP 2018527919A JP 2019501142 A5 JP2019501142 A5 JP 2019501142A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolidine
- carbonitrile
- dioxide
- thiadiazolidine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical compound N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 claims 66
- -1 cyano, hydroxyl Chemical group 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 8
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 208000008425 Protein Deficiency Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000004450 alkenylene group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 125000005418 aryl aryl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004434 sulfur atoms Chemical group 0.000 claims 4
- 201000010874 syndrome Diseases 0.000 claims 4
- 208000006136 Leigh Disease Diseases 0.000 claims 3
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims 3
- 206010061536 Parkinson's disease Diseases 0.000 claims 3
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims 2
- 208000006443 Lactic Acidosis Diseases 0.000 claims 2
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000017094 parkin protein Human genes 0.000 claims 2
- 108091004085 parkin protein Proteins 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 150000003573 thiols Chemical group 0.000 claims 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- YRLORWPBJZEGBX-UHFFFAOYSA-N 3,4-dihydro-2H-1,4-benzoxazine Chemical compound C1=CC=C2NCCOC2=C1 YRLORWPBJZEGBX-UHFFFAOYSA-N 0.000 claims 1
- 208000009270 3-Hydroxyacyl-CoA Dehydrogenase Deficiency Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000004724 Ataxia Neuropathy Spectrum Diseases 0.000 claims 1
- 201000005943 Barth syndrome Diseases 0.000 claims 1
- 102000024678 Bcl-2 family Human genes 0.000 claims 1
- 108091011726 Bcl-2 family Proteins 0.000 claims 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical group C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 claims 1
- 210000000601 Blood Cells Anatomy 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 208000008581 Brain Disease Diseases 0.000 claims 1
- 210000000481 Breast Anatomy 0.000 claims 1
- MJCPNXPIXVSDCM-UHFFFAOYSA-N C(#N)N1CC(CC1)NS(=O)(=O)N1CCC(CC1)C1=CC=CC=C1 Chemical compound C(#N)N1CC(CC1)NS(=O)(=O)N1CCC(CC1)C1=CC=CC=C1 MJCPNXPIXVSDCM-UHFFFAOYSA-N 0.000 claims 1
- YLXVRJJOYCWFAY-UHFFFAOYSA-N C(#N)N1CC(CC1)NS(=O)(=O)N1CCC2=CC=CC=C12 Chemical compound C(#N)N1CC(CC1)NS(=O)(=O)N1CCC2=CC=CC=C12 YLXVRJJOYCWFAY-UHFFFAOYSA-N 0.000 claims 1
- QPXSOTQDCAFXPX-UHFFFAOYSA-N C(#N)N1CC(CC1)NS(=O)(=O)N1CCN(CC1)C1=CC=CC=C1 Chemical compound C(#N)N1CC(CC1)NS(=O)(=O)N1CCN(CC1)C1=CC=CC=C1 QPXSOTQDCAFXPX-UHFFFAOYSA-N 0.000 claims 1
- AHARRWNUCFAGLP-CQSZACIVSA-N C(#N)N1C[C@@H](CC1)NS(=O)(=O)N1CC2=CC=C(C=C2CC1)OC Chemical compound C(#N)N1C[C@@H](CC1)NS(=O)(=O)N1CC2=CC=C(C=C2CC1)OC AHARRWNUCFAGLP-CQSZACIVSA-N 0.000 claims 1
- MTDFSZKLGALOJX-CQSZACIVSA-N C(#N)N1C[C@@H](CC1)NS(=O)(=O)N1CC2=CC=CC=C2CC1 Chemical compound C(#N)N1C[C@@H](CC1)NS(=O)(=O)N1CC2=CC=CC=C2CC1 MTDFSZKLGALOJX-CQSZACIVSA-N 0.000 claims 1
- CVFYNYIRDREIMV-MRXNPFEDSA-N C(#N)N1C[C@@H](CC1)NS(=O)(=O)N1CCC2=C(C=CC=C12)C1=CC=CC=C1 Chemical compound C(#N)N1C[C@@H](CC1)NS(=O)(=O)N1CCC2=C(C=CC=C12)C1=CC=CC=C1 CVFYNYIRDREIMV-MRXNPFEDSA-N 0.000 claims 1
- CQXJRHUVXHVCBE-GOSISDBHSA-N C(#N)N1C[C@@H](CC1)NS(=O)(=O)N1CCC2=CC(=CC=C12)C1=CC=CC=C1 Chemical compound C(#N)N1C[C@@H](CC1)NS(=O)(=O)N1CCC2=CC(=CC=C12)C1=CC=CC=C1 CQXJRHUVXHVCBE-GOSISDBHSA-N 0.000 claims 1
- LEVHNWAKTUBRIB-UHFFFAOYSA-N C1(=CC(=CC=C1)NS(NC1CN(CC1)C#N)(=O)=O)C1=CC=CC=C1 Chemical compound C1(=CC(=CC=C1)NS(NC1CN(CC1)C#N)(=O)=O)C1=CC=CC=C1 LEVHNWAKTUBRIB-UHFFFAOYSA-N 0.000 claims 1
- DBXCMHMITPNPAR-UHFFFAOYSA-N C1(=CC=C(C=C1)NS(NC1CN(CC1)C#N)(=O)=O)C1=CC=CC=C1 Chemical compound C1(=CC=C(C=C1)NS(NC1CN(CC1)C#N)(=O)=O)C1=CC=CC=C1 DBXCMHMITPNPAR-UHFFFAOYSA-N 0.000 claims 1
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical group C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims 1
- 206010007554 Cardiac failure Diseases 0.000 claims 1
- 208000005846 Cardiomyopathy Diseases 0.000 claims 1
- 206010058892 Carnitine deficiency Diseases 0.000 claims 1
- 208000005359 Carnitine palmitoyl transferase 1A deficiency Diseases 0.000 claims 1
- 208000001219 Carnitine palmitoyl transferase 2 deficiency Diseases 0.000 claims 1
- 208000010354 Coenzyme Q10 Deficiency Diseases 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 229960003624 Creatine Drugs 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 1
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 1
- 102000015782 Electron Transport Complex III Human genes 0.000 claims 1
- 108010024882 Electron Transport Complex III Proteins 0.000 claims 1
- 206010014623 Encephalopathy Diseases 0.000 claims 1
- 206010014625 Encephalopathy Diseases 0.000 claims 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 1
- 102100011931 HADH Human genes 0.000 claims 1
- 101710036515 HADH Proteins 0.000 claims 1
- 210000003128 Head Anatomy 0.000 claims 1
- 206010019280 Heart failure Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000004687 Long-chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 208000005548 Medium chain acyl CoA dehydrogenase deficiency Diseases 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 208000004257 Mitochondrial encephalopathy Diseases 0.000 claims 1
- 208000008955 Mucolipidosis Diseases 0.000 claims 1
- 208000001769 Multiple Acyl Coenzyme A Dehydrogenase Deficiency Diseases 0.000 claims 1
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 208000003067 Myocardial Ischemia Diseases 0.000 claims 1
- 208000006625 Myoclonic Epilepsy Diseases 0.000 claims 1
- 206010054859 Myoclonic epilepsy Diseases 0.000 claims 1
- 210000003739 Neck Anatomy 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 208000008760 Optic Nerve Disease Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 210000001672 Ovary Anatomy 0.000 claims 1
- 102100001553 PINK1 Human genes 0.000 claims 1
- 101700023759 PINK1 Proteins 0.000 claims 1
- 102100017629 POLG Human genes 0.000 claims 1
- 101700012117 POLG Proteins 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 206010062941 Pearson's syndrome Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036802 Progressive external ophthalmoplegia Diseases 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- 206010037175 Psychiatric disease Diseases 0.000 claims 1
- 208000010337 Pyruvate Carboxylase Deficiency Disease Diseases 0.000 claims 1
- 208000002009 Pyruvate Dehydrogenase Complex Deficiency Disease Diseases 0.000 claims 1
- 210000002784 Stomach Anatomy 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 210000001550 Testis Anatomy 0.000 claims 1
- 208000005642 VLCAD deficiency Diseases 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 102000003802 alpha-Synuclein Human genes 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- 230000001640 apoptogenic Effects 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 201000008031 cardiomyopathy Diseases 0.000 claims 1
- 201000004010 carnitine palmitoyltransferase I deficiency Diseases 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 201000000915 chronic progressive external ophthalmoplegia Diseases 0.000 claims 1
- 230000001149 cognitive Effects 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000006046 creatine Substances 0.000 claims 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine zwitterion Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 201000011240 frontotemporal dementia Diseases 0.000 claims 1
- 201000010136 inclusion-cell disease Diseases 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 230000000366 juvenile Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 230000002438 mitochondrial Effects 0.000 claims 1
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 claims 1
- 230000004065 mitochondrial dysfunctions Effects 0.000 claims 1
- 201000007769 mucolipidosis Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000001537 neural Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 108010007425 oligomycin sensitivity-conferring protein Proteins 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000010138 pseudo-Hurler polydystrophy Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000006473 pyruvate decarboxylase deficiency Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1521109.7A GB201521109D0 (en) | 2015-11-30 | 2015-11-30 | Novel compounds |
| GB1521109.7 | 2015-11-30 | ||
| PCT/GB2016/053742 WO2017093718A1 (en) | 2015-11-30 | 2016-11-29 | 1-cyano-pyrrolidine derivatives as inhibitors of usp30. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501142A JP2019501142A (ja) | 2019-01-17 |
| JP2019501142A5 true JP2019501142A5 (ru) | 2020-01-16 |
| JP6823064B2 JP6823064B2 (ja) | 2021-01-27 |
Family
ID=55177456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018527919A Active JP6823064B2 (ja) | 2015-11-30 | 2016-11-29 | Ｕｓｐ３０の阻害剤としての１−シアノピロリジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11091488B2 (ru) |
| EP (1) | EP3383859B1 (ru) |
| JP (1) | JP6823064B2 (ru) |
| CN (1) | CN108290861B (ru) |
| ES (1) | ES2807893T3 (ru) |
| GB (1) | GB201521109D0 (ru) |
| WO (1) | WO2017093718A1 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7434285B2 (ja) | 2018-08-14 | 2024-02-20 | アムジエン・インコーポレーテツド | Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014041111A1 (en) * | 2012-09-17 | 2014-03-20 | F. Hoffmann-La Roche Ag | Usp30 inhibitors and methods of use |
| WO2016156816A1 (en) | 2015-03-30 | 2016-10-06 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| EP3800186A1 (en) | 2015-07-14 | 2021-04-07 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| EP3433246B1 (en) * | 2016-03-24 | 2022-05-04 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| WO2018060689A1 (en) | 2016-09-27 | 2018-04-05 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) * | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| US11059809B2 (en) | 2017-06-20 | 2021-07-13 | Mission Therapeutics Limited | Substituted cyanopyrrolidines with activity as DUB inhibitors |
| CN111148743B (zh) | 2017-10-06 | 2023-12-15 | 福马治疗有限公司 | 抑制泛素特异性肽酶30 |
| CA3110113A1 (en) | 2018-10-05 | 2020-04-09 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
| CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| AU2021253617A1 (en) | 2020-04-08 | 2022-12-01 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as USP30 inhibitors |
| BR112022020644A2 (pt) | 2020-05-28 | 2022-12-06 | Mission Therapeutics Ltd | Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial |
| EP4161920A1 (en) | 2020-06-04 | 2023-04-12 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| CA3186148A1 (en) | 2020-06-08 | 2021-12-16 | Mission Therapeutics Limited | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| CN117024329A (zh) * | 2023-06-13 | 2023-11-10 | 北京海望氢能科技有限公司 | 一种n-烷基咔唑的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| TW200922556A (en) | 2007-08-20 | 2009-06-01 | Glaxo Group Ltd | Novel cathepsin C inhibitors and their use |
| US20100331297A1 (en) * | 2007-11-07 | 2010-12-30 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| AR071480A1 (es) | 2008-04-18 | 2010-06-23 | Glaxo Group Ltd | Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd ) |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| AR071369A1 (es) | 2008-04-18 | 2010-06-16 | Glaxo Group Ltd | Compuesto de 1- ciano-3-pirrolidinil-n-sustituido-sulfonamida, su uso para preparar un medicamento util para tratar una enfermedad pulmonar obstructiva cronica y composicion farmaceutica que lo comprende |
| SG182662A1 (en) * | 2010-01-28 | 2012-08-30 | Harvard College | Compositions and methods for enhancing proteasome activity |
| JP2016537316A (ja) * | 2013-10-10 | 2016-12-01 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| WO2016156816A1 (en) * | 2015-03-30 | 2016-10-06 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| EP3800186A1 (en) | 2015-07-14 | 2021-04-07 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| EP3433246B1 (en) | 2016-03-24 | 2022-05-04 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| WO2018060689A1 (en) | 2016-09-27 | 2018-04-05 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
-
2015
- 2015-11-30 GB GBGB1521109.7A patent/GB201521109D0/en not_active Ceased
-
2016
- 2016-11-29 WO PCT/GB2016/053742 patent/WO2017093718A1/en active Application Filing
- 2016-11-29 CN CN201680069597.2A patent/CN108290861B/zh active Active
- 2016-11-29 US US15/776,149 patent/US11091488B2/en active Active
- 2016-11-29 JP JP2018527919A patent/JP6823064B2/ja active Active
- 2016-11-29 ES ES16808743T patent/ES2807893T3/es active Active
- 2016-11-29 EP EP16808743.5A patent/EP3383859B1/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7434285B2 (ja) | 2018-08-14 | 2024-02-20 | アムジエン・インコーポレーテツド | Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501142A5 (ru) | ||
| JP2018524367A5 (ru) | ||
| JP2019504009A5 (ru) | ||
| JP2019533659A5 (ru) | ||
| US10689345B2 (en) | 1-cyano-pyrrolidine compounds as USP30 inhibitors | |
| US11958833B2 (en) | Compounds | |
| JP2019513135A5 (ru) | ||
| US11945797B2 (en) | 1-cyano-pyrrolidine derivatives as dub inhibitors | |
| JP2020521730A5 (ru) | ||
| JP2019532945A5 (ru) | ||
| US10669234B2 (en) | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | |
| JP2019532950A5 (ru) | ||
| JP2019532938A5 (ru) | ||
| JP2019503362A5 (ru) | ||
| JP2018510183A5 (ru) | ||
| US20200017480A1 (en) | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 | |
| EP3519412A1 (en) | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 | |
| JP2019533659A (ja) | Ｕｓｐ３０の阻害剤としての活性を有するシアノ置換ヘテロ環 | |
| EP3394049A1 (en) | Cyanopyrrolidine derivatives as inhibitors for dubs | |
| JP2013533879A5 (ru) | ||
| JP2020524166A5 (ru) | ||
| WO2014147586A1 (en) | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh | |
| JP2017528515A5 (ru) | ||
| JP2017532360A5 (ru) | ||
| JPWO2021050824A5 (ru) |